Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 18, 2024 4:08pm
76 Views
Post# 35939062

RE:RE:RepliCel Life signs LOI with CEO for asset purchase

RE:RE:RepliCel Life signs LOI with CEO for asset purchaseBluemoons20 you will now own shares in this new private company  which is: 

"(the purchaser), a non-arm's-length private British Columbia company owned and controlled by Andrew Schutte."

 You may be a bit confused on the sale of the assets.  The sale of the assets is from Replicel to this new company headed up by Andrew Schutte:

"The LOI stipulates that the assets will be purchased from RepliCel in exchange for an 8-per-cent royalty on all gross profits earned by the purchaser in relation to the sale of DermaPrecise, RCH, RCT and RCS, or their improvements, after completion of the proposed transaction."


This in essence is a "hail mary" to avoid bankruptcy.  At this point if we have any chance to recover any part of our investment this is our only choice.  
 

<< Previous
Bullboard Posts
Next >>